 
Alpelisib
Phosphatidylinositol 3-Kinase alpha-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D
 Rodon J
 Tabernero J
 Janku F
 Burris HA
 Schellens JHM
 Middleton MR
 Berlin J
 Schuler M
 Gil-Martin M
 Rugo HS
 Seggewiss-Bernhardt R
 Huang A
 Bootle D
 Demanse D
 Blumenstein L
 Coughlin C
 Quadt C
 Baselga J.

Gedatolisib
First-in-Human Study of PF-05212384 (PKI-587)
 a Small-Molecule
 Intravenous
 Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Shapiro GI
 Bell-McGuinn KM
 Molina JR
 Bendell J
 Spicer J
 Kwak EL
 Pandya SS
 Millham R
 Borzillo G
 Pierce KJ
 Han L
 Houk BE
 Gallo JD
 Alsina M
 Braña I
 Tabernero J.

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Curigliano G
 Shapiro GI
 Kristeleit RS
 Abdul Razak AR
 Leong S
 Alsina M
 Giordano A
 Gelmon KA
 Stringer-Reasor E
 Vaishampayan UN
 Middleton M
 Olszanski AJ
 Rugo HS
 Kern KA
 Pathan N
 Perea R
 Pierce KJ
 Mutka SC
 Wainberg ZA.


Copanlisib

First-in-human phase I study of copanlisib (BAY 80-6946)
 an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor
 in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Patnaik A
 Appleman LJ
 Tolcher AW
 Papadopoulos KP
 Beeram M
 Rasco DW
 Weiss GJ
 Sachdev JC
 Chadha M
 Fulk M
 Ejadi S
 Mountz JM
 Lotze MT
 Toledo FG
 Chu E
 Jeffers M
 Peña C
 Xia C
 Reif S
 Genvresse I
 Ramanathan RK

Pilaralisib
Phase I safety
 pharmacokinetic
 and pharmacodynamic study of SAR245408 (XL147)
 an oral pan-class I PI3K inhibitor
 in patients with advanced solid tumors.
Shapiro GI
 Rodon J
 Bedell C
 Kwak EL
 Baselga J
 Braña I
 Pandya SS
 Scheffold C
 Laird AD
 Nguyen LT
 Xu Y
 Egile C
 Edelman G.

Serabelisib
A First-in-Human
 Phase I
 Dose-Escalation Study of TAK-117
 a Selective PI3Kα Isoform Inhibitor
 in Patients with Advanced Solid Malignancies.
Juric D
 de Bono JS
 LoRusso PM
 Nemunaitis J
 Heath EI
 Kwak EL
 Macarulla Mercadé T
 Geuna E
 Jose de Miguel-Luken M
 Patel C
 Kuida K
 Sankoh S
 Westin EH
 Zohren F
 Shou Y
 Tabernero J.

High impact reviews:
PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck 
Matthew W. D. Perry  
Jennifer R. Brown
Fabrice André & Klaus Okkenhaug 
Nature Reviews Drug Discovery volume 20
 pages741–769 (2021)

At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Neil Vasan &  Lewis C. Cantley 
Nature Reviews Clinical Oncology volume 19
 pages471–485 (2022)

The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj & Brendan D. Manning 
Nature Reviews Cancer volume 20
 pages74–88 (2020)

PI3K and cancer: lessons
 challenges and opportunities
David A. Fruman & Christian Rommel 
Nature Reviews Drug Discovery volume 13
 pages140–156 (2014)
The present and future of PI3K inhibitors for cancer therapy
Pau Castel
1
Eneda Toska
2
3
Jeffrey A. Engelman
4 and Maurizio Scaltriti5
Nat cancer 2021

